You are using an older version of Internet Explorer that is not supported on this site. Please upgrade for the best experience.

Pancreatic Cancer Trials

Click on a trial to find out the eligibility requirements and who to contact if you have questions about participating.

Page 1 of 1 | Results 1 - 6 of 6

A Phase II-R and a Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

The purpose of this study is to evaluate the effects (good and bad) of the use of radiation after completion of gemcitabine
Seth Kaufman, MD
Cancer, Cancer - Pancreatic

D’Amour Center for Cancer Care

3350 Main Street, Springfield MA 01199

NCI/CIRB EAY131 Molecular Analysis for Therapy Choice (MATCH)

John McCann, MD
Cancer, Cancer - Brain, Cancer - Breast, Cancer - Colon, Cancer - Esophogus, Cancer-Gynecologic, Cancer - Kidney, Cancer - Leukemia, Cancer - Lung, Cancer - Lymphoma, Cancer - Melanoma, Cancer - Multiple Myeloma, Cancer - Pancreatic, Cancer - Prostate

D'Amour Center For Cancer Care

3350 Main Street
Springfield, MA 01199

NCI/CIRB S1505 A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

The purpose of this study is to compare the effects of mFOLFIRINOX (oxaliplatin, irinotecan, and fluorouracil) and gemcitabine plus nab-paclitaxel. These chemotherapy drugs will be given before and after surgery. This study will allow the researchers to know if it is a good idea to treat pancreatic cancer with chemotherapy drugs before surgery and if so, to see which of the two drug combinations is better.
Chandravathi Loke, MD
Cancer - Pancreatic, Cancer

Damour Center for Cancer Care

NCI/CIRB S1609 DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS

John McCann, MD
Cancer, Cancer - Brain, Cancer - Breast, Cancer - Colon, Cancer - Esophogus, Cancer-Gynecologic, Cancer - Kidney, Cancer - Leukemia, Cancer - Lung, Cancer - Lymphoma, Cancer - Melanoma, Cancer - Multiple Myeloma, Cancer - Pancreatic, Cancer - Prostate

D'Amour Center for Cancer Care

3350 Main Street
Springfield, MA 01199

Phase II-R and a Phase III Trial Evaluating Both Erlotinib (PH II R) and Chemoradiation (PH III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

This clinical trial evaluates:

  • the effects of the addition of erlotinib to gemcitabine compared to gemcitabine alone following pancreas adenocarcinoma surgery
  • whether the use of fluoropyrimidine and radiotherapy following adjuvant gemcitabine based chemotherapy further enhances survival for such patients who are without evidence of progressive disease after 5 cycles of gemcitabine based chemotherapy.
Seth Kaufman, MD
Cancer, Cancer - Pancreatic

D'Amour Center for Cancer Care
3350 Main Street
Springfield, MA

Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

The purpose of this study is to compare the effects of mFOLFIRINOX (oxaliplatin, irinotecan, and fluorouracil) and gemcitabine plus nab-paclitaxel. These chemotherapy drugs will be given before and after surgery. This study will allow the researchers to know if it is a good idea to treat pancreatic cancer with chemotherapy drugs before surgery and if so, to see which of the two drug combinations is better.

Chandravathi Loke, MD
Cancer - Pancreatic, Cancer

D'amour Center for Cancer Care
3350 Main Street
Springfield MA 01199

Page 1 of 1 | Results 1 - 6 of 6